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Radiation oncologists are often challenged because of 
the paucity of randomised trials supporting their clinical 
practice. In terms of brain metastases treatment, it should 
be emphasised that there have been ﬁ ve randomised trials 
assessing whole brain radiotherapy (WBRT): four studies1–4 
assessing stereotactic radio therapy with or without 
WBRT for patients with four or less brain metastases, 
and the present trial by Paula Mulvenna and colleagues5 
in The Lancet assessing optimum supportive care with or 
without WBRT in a much poorer prognostic population of 
patients with non-small-cell lung cancer (NSCLC). None 
of these trials has shown any survival improvement with 
WBRT, but the ﬁ rst four have shown improved intracranial 
control with the addition of WBRT. It is only in small-cell 
lung cancer that prophylactic WBRT improves survival 
because emergence and development of brain metastases 
is prevented; but this does not apply to patients with 
NSCLC6 Because of advances in the management of 
NSCLC, the risk of developing brain metastases seems to 
increase as survival is prolonged. NSCLC management in 
2016 still represents a real challenge because detectable 
brain metastases might be responsible for life-threatening 
symptoms and serious impairment of quality of life, 
possibly ameliorated with WBRT.7
Mulvenna and colleagues are to be congratulated for 
conducting this non-inferiority phase 3 trial assessing 
the omission of WBRT in patients with NSCLC and brain 
metastases.5 They chose quality-adjusted life-years 
(QALYs) as the primary outcome measure, and a 
group of 538 patients between 2007 and 2014 were 
randomly assigned to receive either WBRT (20 Gy in ﬁ ve 
daily fractions) and optimal supportive care, including 
dexamethasone (n=269), or optimal supportive care 
alone (n=269). The beneﬁ ts in terms of length of life were 
adjusted to reﬂ ect the quality of life assessed with weekly 
questionnaires. 536 patients died by October, 2015. 
The authors concluded that there was no evidence of a 
diﬀ erence in terms of QALYs, overall survival (hazard ratio 
[HR] 1·06, 95% CI 0·90–1·26), or quality of life; the median 
survival from randomisation was less than 3 months. 
The diﬀ erence between the mean QALYs was 4·7 days 
(46·4 QALY days for the optimal supportive care plus 
WBRT group vs 41·7 QALY days for the optimal supportive 
care only group), with two-sided 90% CI of –12·7 to 3·3.
There is no question that this is a large and well 
designed trial, and that patients were well assessed, with 
more than 90% of the expected follow-up forms and 
more than 80% of the quality-of-life forms received. 
It should be emphasised that owing to poor survival, 
only 289 (53%, 149 WBRT patients and 140 optimal 
supportive care patients who were assessed for quality 
of life at 4 weeks) and 97 (18%, 54 WBRT patients 
and 43 optimal supportive care patients assessed at 
12 weeks) of all enrolled patients answered quality-of-
life questionnaires at 4 weeks and 12 weeks, respectively. 
Should we then consider that there is no place for WBRT 
Whole brain radiotherapy in patients with NSCLC and 
brain metastases
3 Hansen ML, Jepsen RM, Olesen JB, et al. Thromboembolic risk in 
16 274 atrial ﬁ brillation patients undergoing direct current cardioversion 
with and without oral anticoagulant therapy. Europace 2015; 17: 18–23.
4 Klein AL, Grimm RA, Murray RD, et al, for the Assessment of Cardioversion 
Using Transesophageal Echocardiography Investigators. Use of 
transesophageal echocardiography to guide cardioversion in patients with 
atrial ﬁ brillation. N Engl J Med 2001; 344: 1411–20.
5 Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin 
in patients with atrial ﬁ brillation: an analysis of patients undergoing 
cardioversion. Circulation 2011; 123: 131.
6 Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes following cardioversion 
and atrial ﬁ brillation ablation in patients treated with rivaroxaban and 
warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013; 61: 1998–2006.
7 Flaker G, Lopes RD, Al Khatib SM, et al. Eﬃ  cacy and safety of apixaban in 
patients after cardioversion for atrial ﬁ brillation: insights from the ARISTOTLE 
Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation). J Am Coll Cardiol 2014; 63: 1082–87.
8 Cappato R, Ezekowitz MD, Klein AL, et al, on behalf of the X-VeRT 
Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in 
atrial ﬁ brillation. Eur Heart J 2014; 35: 3346–55.
9 Ruﬀ  CT, Giugliano RP, Braunwald E, et al. Comparison of the eﬃ  cacy and 
safety of new oral anticoagulants with warfarin in patients with atrial 
ﬁ brillation: a meta-analysis of randomised trials. Lancet 2014; 383: 955–62.
10 Coleman CM, Khalaf S, Mould S, et al. Novel oral anticoagulants for DC 
cardioversion procedures: utilization and clinical outcome compared with 
warfarin. Pacing Clin Electrophysiol 2015; 38: 731–37.
11 Janua ry CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial ﬁ brillation: a report of the American 
College of Cardiology/American Heart Association Task Force on Practice 
Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 
130: 2071–104.
12 Goette A, Merino JL, Ezekowitz M, et al. Edoxaban versus 
enoxaparin–warfarin in patients undergoing cardioversion of atrial 
ﬁ brillation (ENSURE-AF): a randomized, open-label, phase 3b trial. 
Lancet 2016; published online Aug 30. http://dx.doi.org/10.1016/
S0140-6736(16)31474-X.
Published Online
September 4, 2016
http://dx.doi.org/10.1016/
S0140-6736(16)31391-5
See Articles page 2004
Ze
ph
yr
/S
cie
nc
e 
Ph
ot
o 
Li
br
ar
y 
Comment
www.thelancet.com   Vol 388   October 22, 2016 1961
in such a group of patients with NSCLC because it gives 
little, if any, additional clinically signiﬁ cant beneﬁ t?
The limitations of the study include that it is generally 
accepted that the maximum beneﬁ t of radiotherapy is 
achieved 6 weeks after the end of the treatment. Given 
the median overall survival of 8 weeks and considering 
the time to deliver WBRT, about half of patients died 
before an optimum symptomatic assessment could be 
done. This might also explain why WBRT did not have any 
eﬀ ect on steroid consumption, because patients did not 
live long enough for an eﬀ ect to be seen. Of course, the 
decision to deliver WBRT should be put into perspective 
with the fatigue and neurocognitive toxicity it might 
generate. This trial raises another question: are the 
conclusions applicable to patients with NSCLC treated by 
today’s standards? A one size ﬁ ts all policy was applied 
to all eligible patients, ranging from those unsuitable for 
surgery or stereotactic cranial radiotherapy to any patient 
for whom there was uncertainty over the beneﬁ t of WBRT. 
As expected, the population was quite heterogeneous, 
but of poor outcome. The recursive partitioning analysis 
(RPA) and DS-GPA (Diagnosis Speciﬁ c Graded Prognostic 
Assessment) prognostic classes taking into account 
Karnofsky performance status (KPS), age, presence of 
extracranial disease, and status of primary tumour or 
number of brain metastases were designed to select the 
patients most eligible for radiotherapy.8 As an example, 
this trial conﬁ rms that WBRT should not be given to 
RPA class 3 patients, which represented more than a 
third of the enrolled population. There was no evidence 
that WBRT oﬀ ered a survival advantage within any 
prognostic class, but this should be interpreted with 
caution. The results of this trial emphasise the robustness 
of prognostic factors such as age and KPS.5 Improved 
survival with WBRT was indeed shown for younger 
patients, particularly those younger than 60 years, and 
there was a trend for better outcome in patients with 
a KPS of at least 70 and those with controlled primary 
NSCLC. It now seems clear that an elderly patient, with 
a KPS of less than 70 and uncontrolled primary, should 
not have WBRT. Indications of stereotactic radiotherapy 
have become broader, especially in elderly patients and in 
patients with expected longer term survival.9,10
As outlined by the authors, there have been considerable 
changes within the past 10 years in the systemic 
treatment of patients with advanced NSCLC, but also 
in the development and widespread use of stereotactic 
radiotherapy and MRI to strictly monitor some of 
these patients who might need several treatments. 
Identiﬁ cation of oncogenic driver mutations, and more 
sophisticated pre-treatment tumour characterisation 
has transformed the outcome of a subgroup of patients 
with metastatic NSCLC; survival has been increased by at 
least three times over the past 15 years in patients with 
epidermal growth factor receptor (EGFR)-mutated or 
anaplastic lymphoma kinase (ALK)-rearranged NSCLC. 
EGFR mutation as well as the absence of (or little) tobacco 
consumption, considered as a surrogate marker of these 
molecular abnormalities, were not captured in this study, 
and this is another key limitation to the interpretation 
of these results. The intracranial eﬃ  cacy of targeted 
drugs such as EGFR tyrosine kinase inhibitors (TKI) or 
ALK inhibitors has been shown, justifying their use as 
ﬁ rst-line treatment in case of EGFR mutation or ALK 
rearrangement.11,12 WBRT might also enhance penetration 
of some drugs, thus possibly improving their eﬃ  cacy.13
Finally, this trial might not rule out use of WBRT in 
all patients with NSCLC and brain metastases. Is there 
still a place for WBRT in patients with NSCLC and brain 
metastases? Yes, we believe that optimised WBRT, given 
at the right time to appropriate patients, could lead to 
more individualised strategies. Both systemic and local 
treatments of brain metastases need to be discussed 
with patients, taking into account the results of this trial, 
classic prognostic factors, and the molecular status.
*Cécile Le Pechoux, Frederic Dhermain, Benjamin Besse
Department of Radiation Oncology (CLP, FD) and Department of 
Medical Oncology (BB), Gustave Roussy Cancer Campus, Villejuif 
94800, France; and Faculté de Médecine, Université Paris Sud, 
Le Kremlin-Bicêtre, France (BB)
cecile.lepechoux@gustaveroussy.fr
We declare no competing interests.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article 
under the CC BY-NC-ND license.
1 Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus 
whole-brain radiation therapy vs stereotactic radiosurgery alone for 
treatment of brain metastases: a randomized controlled trial. JAMA 2006; 
295: 2483–91.
2 Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain 
metastases treated with radiosurgery or radiosurgery plus whole-brain 
irradiation: a randomised controlled trial. Lancet Oncol 2009; 10: 1037–44.
3 Kocher M, Soﬃ  etti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy 
versus observation after radiosurgery or surgical resection of one to three 
cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 
2011; 29: 134–41.
4 Brown PD, Asher AL, Ballman KV, et al. NCCTG N0574 (Alliance): a phase III 
randomized trial of whole brain radiation therapy (WBRT) in addition to 
radiosurgery (SRS) in patients with 1–3 brain metastases. J Clin Oncol 2015; 
33 (suppl 15): LBA4 (abstr).
Comment
1962 www.thelancet.com   Vol 388   October 22, 2016
Outcomes of patients with acute coronary syndrome 
undergoing percutaneous coronary intervention have 
been signiﬁ cantly improved with the potent P2Y12 
receptor inhibitors prasugrel and ticagrelor.1,2 Elderly 
patients comprise a growing subset of the acute coronary 
syndrome population. This subset is characterised by 
multiple organ changes and various comorbidities, 
which altogether culminate in an increased risk of both 
ischaemic and bleeding complications after percutaneous 
coronary intervention. Platelet function testing has 
been established and validated to predict ischaemic and 
bleeding events in patients treated with percutaneous 
coronary intervention.3,4 However, previous studies,5,6 
enrolling mostly low-risk patients with little use of potent 
antiplatelet drugs, have been unable to show clinical 
superiority of strategies that implemented platelet 
function testing for treatment guidance. Nevertheless, 
elderly patients undergoing percutaneous coronary 
intervention represent a high-risk cohort that might 
derive clinical beneﬁ t from platelet function testing to 
monitor and adjust the level of platelet inhibition.
In The Lancet, Guillaume Cayla and colleagues report the 
results of the randomised controlled ANTARCTIC trial,7 
which assessed the eﬀ ect of platelet function monitoring 
with treatment adjustment in 877 elderly patients (aged 
≥75 years) stented for an acute coronary syndrome. 
The investigators aimed to establish the superiority of a 
platelet function monitoring-guided treatment approach 
using the VerifyNow assay (monitoring strategy) with 
options to escalate (from 5 mg to 10 mg prasugrel) or 
de-escalate (from 5 mg prasugrel to clopidogrel 75 mg) 
the level of platelet inhibition, compared with a uniform 
treatment approach (control strategy) of prasugrel 5 mg 
daily with no testing or treatment adjustment. As a key 
result of the study, the primary composite endpoint 
of cardiovascular death, myocardial infarction, stroke, 
stent thrombosis, urgent revascularisation, and bleeding 
complications after 12 months did not diﬀ er between 
the two treatment groups (hazard ratio 1·003, 95% CI 
0·78–1·29; p=0·98); ischaemic complications (p=0·80) and 
bleeding events alone (p=0·77) were likewise non-
signiﬁ cant. On the basis of these results, the investigators 
conclude that platelet function monitoring to adjust 
low-dose prasugrel treatment in elderly patients with 
acute coronary syndrome does not improve their clinical 
outcome. Cayla and colleagues are to be congratulated 
for this important and well conducted study of platelet 
function monitoring to guide treatment speciﬁ cally in 
elderly patients, who are generally under-represented in 
clinical trials. However, some important caveats should 
be considered that might explain why ANTARCTIC did not 
show a net clinical beneﬁ t of the monitoring approach.
First, the study was designed with an initial treatment 
strategy of low-dose prasugrel for both groups. Platelet 
function monitoring in the monitoring group resulted 
in only 16 (4%) of 435 patients requiring intensiﬁ cation 
of treatment (up-adjustment to prasugrel 10 mg). 
In fact, the predominant consequence of testing was 
de-escalation of treatment with a change of treatment 
from low-dose prasugrel to clopidogrel in 171 (39%) 
patients, while 240 (55%) patients in the monitoring 
group remained on prasugrel 5 mg. In essence, 
ANTARCTIC therefore compared the eﬀ ect of prasugrel 
5 mg with a regimen in which low-dose prasugrel 
was replaced by clopidogrel 75 mg in less than half of 
patients. Against this background, invasively managed 
Antiplatelet strategies in elderly people: still a long way to go 
5 Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive 
care with or without whole brain radiotherapy in treating patients with 
non-small cell lung cancer with brain metastases unsuitable for resection or 
stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, 
randomised trial. Lancet 2016; published online Sept 4. http://dx.doi.
org/10.1016/S0140-6736(16)30825-X.
6 Le Pechoux C, Sun A, Slotman BJ, De Ruysscher D, Belderbos J, Gore E. 
Prophylactic cranial irradiation for patients with lung cancer. 
Lancet Oncol 2016; 17: e277–93.
7 Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain 
radiation therapy for brain metastases correlates with survival and improved 
neurocognitive function. J Clin Oncol 2007; 25: 1260–66.
8 Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded 
prognostic assessment: an accurate and facile diagnosis-speciﬁ c tool to 
estimate survival for patients with brain metastases. J Clin Oncol 2012; 
30: 419–25.
9 Yamamoto M, Serizawa T, Shuto T, et al. Stereotactic radiosurgery for 
patients with multiple brain metastases (JLGK0901): a multi-institutional 
prospective observational study. Lancet Oncol 2014; 15: 387–95.
10 Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung 
Cancer: non-small-cell lung cancer ﬁ rst-line/second and further lines of 
treatment in advanced disease. Ann Oncol 2014; 25: 1475–84.
11 Zhang I, Zaorsky NG, Palmer JD, Mehra R, Lu B. Targeting brain metastases in 
ALK-rearranged non-small-cell lung cancer. Lancet Oncol 2015; 16: e510–21.
12 Heon S, Yeap BY, Lindeman NI, et al. The impact of initial geﬁ tinib or 
erlotinib versus chemotherapy on central nervous system progression in 
advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res 
2012; 18: 4406–14.
13 Shi W, Dicker AP. CNS metastases in patients with non-small-cell lung cancer 
and ALK gene rearrangement. J Clin Oncol 2016; 34: 107–09.
Published Online
August 28, 2016
http://dx.doi.org/10.1016/
S0140-6736(16)31387-3
See Articles page 2015
